Celsion Corporation Company Profile
Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.
News Articles
Hisun To Sell Celsion’s ThermoDox In China; Net Profit May Drop 35-45%
Zhejiang Hisun Pharmaceutical Co., Ltd. signed a letter of intent with U.S.-based Celsion Corporation to exclusively market Celsion’s patented anti-tumor drug ThermoDox (available for infusion or ra...
Celsion’s R&D Improves After Split With Hisun
After Celsion and Zhejiang Hisun Pharmaceutical Co., Ltd.’s terminated their collaboration for cancer treatment ThermoDox in China due to failure to reach set clinical trial targets, the project, no...
Celsion Rises After Expanding China Partnership
From Associated Press (January 22, 2013) NEW YORK -- Shares of Celsion Corp. climbed Tuesday after the company expanded a drug development deal with a Chinese pharmaceutical company. THE SPARK: Celsio...
A Quick Take: Celsion’s ThermoDox Phase III Failure Deals Blow To Hisun
With the ink barely dry in a deal between U.S. biotech Celsion and Chinese active ingredient manufacturer Hisun for Celsion’s leading oncology candidate ThermoDox, a Phase III study has thrown both...
A Quick Take: Celsion’s ThermoDox Phase III Failure Deals Blow To China’s Hisun
With the ink barely dry in a deal between U.S. biotech Celsion and Chinese active ingredient manufacturer Hisun for Celsion’s leading oncology candidate ThermoDox, a Phase III study has thrown both...
Celsion’s Cancer Med R&D Improves, Co-Op With Hisun Pharma Ends
After Celsion Corporation and Zhejiang Hisun Pharmaceutical Co., Ltd.’s R&D and marketing collaboration for cancer treatment ThermoDox in China terminated due to failure to reach their set clini...
New Jersey-Based Celsion’s ThermoDox Phase III Failure Deals Blow To China’s Hisun
With the ink barely dry in a deal between U.S. biotech Celsion and Chinese active ingredient manufacturer Hisun for Celsion’s leading oncology candidate ThermoDox, a failed Phase III study has throw...
Refocused, Reframed And Patiently Awaiting Celsion's Real Results After This Week's Chaos
ByQuoth the Raven:The past week has been nothing short of an absolute roller-coaster ride for those watching Celsion (CLSN), one of the most squawked about biotech companies on the market right now. T...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-...
Founded in 1982, with a vision of using heat to kill cancer and treat other diseases, Celsion began trading publicly in 1985 under the name Cheung Laboratories, Inc. The early research focus of the Co...
More Information about "Celsion Corporation" on BioPortfolio
We have published hundreds of Celsion Corporation news stories on BioPortfolio along with dozens of Celsion Corporation Clinical Trials and PubMed Articles about Celsion Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celsion Corporation Companies in our database. You can also find out about relevant Celsion Corporation Drugs and Medications on this site too.
